OCI priorities include:
- Breaches in the legitimate medical supply chain by individuals and organizations dealing in unapproved, counterfeit, and substandard medical products
- Criminal violations in situations where the normal regulatory process has been unable to remedy the problem
- Criminal violations where the risk of harm to the public health is particularly significant and the only remedy appears to be through the criminal process
- Criminal conduct that prevents the FDA from being able to properly regulate. This includes false statements to the FDA during the regulatory process and obstruction of justice.